Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-800CW for PitNET detection during surgery
NCT04212793Phase 1Completed
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2020
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of bevacizumab-IRDye800CW in pituitary neuroendocrine tumor (PitNET) (3 arms), sponsored by University Medical Center Groningen. Primary endpoints: Discrimination of tumorous and non-tumorous tissue at 3 days and Number of participants with adverse events at 7 days. Started Oct 2020; status: completed.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
pituitary neuroendocrine tumor (PitNET)
Beyond the preview
Go deeper on NCT04212793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04212793.